Redirecting TGF-β signalling, inspired by adaptive evolution of parasite mimics.
In plain English
AI plain-English summaryA parasitic worm’s evolutionary toolkit is teaching researchers how to hijack a single human signalling pathway in multiple, cell-specific ways—without the toxic side effects that have plagued drug development for decades. The Transforming Growth Factor-β (TGF-β) pathway is essential for tissue maintenance and immune regulation, but when it goes wrong it drives cancer and fibrosis. Drugs that block the pathway broadly cause severe side effects because TGF-β acts on nearly every cell type. The parasite *Heligmosomoides polygyrus* secretes modular proteins—TGF-β mimics (TGMs)—that bind different co-receptors on different cells: TGM1 and TGM4 target CD44 on blood cells, TGM6 targets LRP1 on fibroblasts, and TGM7 targets gp130 on liver cells. Some TGMs activate signalling, others block it, depending on the cell type. This is a level of precision the human cytokine itself cannot achieve. If the researchers can reverse-engineer these modular structures, they could design drugs that either boost or suppress TGF-β signalling in specific tissues—turning off fibrosis in the lungs without disrupting immune function elsewhere, or promoting regulatory immune cells in autoimmune disease without affecting wound healing. This is fundamental science, inspired by an evolutionary arms race, with direct potential to reshape how we treat a broad class of chronic diseases.
View original technical description
View the original record at the funder ↗
Researchers
Related Research
Grants with similar aims, by meaning.
Original classification
Discovery AwardPlain English summaries and category classifications on this site are generated by AI and may not perfectly reflect the original research. Is something wrong? Let us know